DNA X regains Nasdaq $2.5M equity compliance
Rhea-AI Filing Summary
DNA X, Inc. (SONM) reports that a Nasdaq Hearings Panel has determined the company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies on the Nasdaq Capital Market to maintain at least $2.5 million of stockholders’ equity. Under a prior Panel decision, the company’s securities remain subject to delisting if it fails to comply with all Nasdaq listing rules through November 18, 2026. In addition, under Nasdaq Listing Rule 5815(d)(4)(B), the company will be under a mandatory panel monitor until August 28, 2027. If during that one-year monitoring period Nasdaq staff again finds the company below the stockholders’ equity requirement, staff must issue a delisting determination without allowing a compliance plan or cure period, although the company could request a new hearing and its securities may then be delisted.
Positive
- Regained Nasdaq equity compliance: A Nasdaq Hearings Panel notified the company that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires at least $2.5 million in stockholders’ equity, reducing immediate delisting risk.
Negative
- Extended Nasdaq monitoring and delisting risk: The company remains subject to delisting if it fails to comply with all Nasdaq listing rules through November 18, 2026, and will face a mandatory panel monitor until August 28, 2027, with no cure period if equity falls below the required level again.
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Stockholders’ equity requirement: $2.5 million
Panel decision monitoring cutoff: November 18, 2026
Mandatory panel monitor end date: August 28, 2027
+1 more
4 metrics
Stockholders’ equity requirement
$2.5 million
Minimum stockholders’ equity required by Nasdaq Listing Rule 5550(b)(1)
Panel decision monitoring cutoff
November 18, 2026
Date until which SONM’s securities remain subject to delisting if listing rules are not maintained
Mandatory panel monitor end date
August 28, 2027
End of one-year mandatory monitoring period under Nasdaq Listing Rule 5815(d)(4)(B)
Par value of common stock
$0.001 per share
Par value of DNA X, Inc. common stock listed on Nasdaq
Key Terms
Nasdaq Listing Rule 5550(b)(1), Stockholders’ Equity Requirement, mandatory panel monitor, delisting determination letter, +1 more
5 terms
Nasdaq Listing Rule 5550(b)(1) regulatory
"determined that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1)"
Stockholders’ Equity Requirement financial
"to maintain stockholders’ equity of at least $2.5 million (the “Stockholders’ Equity Requirement”)"
A stockholders’ equity requirement is a minimum amount of net assets — assets minus liabilities — that a company must keep on its balance sheet to meet rules set by regulators, lenders or stock exchanges. Think of it as a required safety buffer or minimum bank balance that shows the company has enough of its own capital to absorb losses; falling below it can limit dividends, trigger covenants or risk sanctions, so investors watch it as a sign of financial health and compliance.
mandatory panel monitor regulatory
"the Company will be subject to a mandatory panel monitor until August 28, 2027"
A mandatory panel monitor is an independent group tasked with regularly reviewing safety and key results during a clinical trial or regulated program to protect participants and ensure the study is conducted properly. For investors, this matters because the panel can recommend changes, pauses, or early stopping of a trial — actions that can speed up, delay, or quietly derail a program and therefore materially affect a company’s timeline and value, much like a referee whose calls change the outcome of a game.
delisting determination letter regulatory
"Instead, the Staff will issue a delisting determination letter, and the Company"
A delisting determination letter is a formal notice from a stock exchange saying a company no longer meets the exchange’s listing rules and is facing removal from the market. Think of it as an eviction notice for a building: the company’s shares may lose the convenience of regular trading, become harder to sell, and often fall in value, so investors should reassess liquidity, price risk, and any underlying operational or compliance problems.
Nasdaq Listing Rule 5815(d)(4)(B) regulatory
"Pursuant to Nasdaq Listing Rule 5815(d)(4)(B), the Company will be subject"
FAQ
What Nasdaq listing issue did DNA X, Inc. (SONM) address in this 8-K?
DNA X, Inc. reported that a Nasdaq Hearings Panel determined it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires at least $2.5 million of stockholders’ equity for continued listing on the Nasdaq Capital Market.
What is the stockholders’ equity requirement mentioned for SONM?
The filing cites Nasdaq Listing Rule 5550(b)(1), which requires companies on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2.5 million to remain in compliance with Nasdaq listing standards.
How long does DNA X, Inc. (SONM) remain at risk of delisting under the Panel decision?
Under the Panel’s July 24, 2026 decision, SONM’s securities remain subject to delisting if it fails to comply with all Nasdaq listing rules until November 18, 2026, even though it has currently regained equity compliance.
What is the mandatory panel monitor period for DNA X, Inc. (SONM)?
Under Nasdaq Listing Rule 5815(d)(4)(B), DNA X, Inc. will be subject to a mandatory panel monitor until August 28, 2027, during which renewed non-compliance with the equity rule would trigger an automatic delisting determination.
What happens if SONM again falls below the Nasdaq equity requirement during monitoring?
If DNA X, Inc. again fails the Stockholders’ Equity Requirement during the one-year monitoring period, Nasdaq staff must issue a delisting determination letter without allowing a compliance plan or cure period, though the company may request a new hearing with a Panel.
AI-generated analysis. How Rhea-AI works. Not financial advice.
